Evidence map›Paper›PMID 20854180›Full record

ReviewExpert opinion on therapeutic targets2010

Targeting Fas in osteoresorptive disorders.

Natasa Kovacic, Danka Grcevic, Vedran Katavic, Ivan Kresimir Lukic, Ana Marusic

Registry-linked trialOpen access · greenAbstract readReview
In one paragraph

Review in Expert opinion on therapeutic targets, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01832311 (Protein Profile of Immunoregulatory Factors in Diabetic Cataract), which is not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01832311 phase4completednot on this map

Protein Profile of Immunoregulatory Factors in Diabetic Cataract

TypeinterventionalSponsorUniversity of ZagrebRan2009 to 2012Enrolled61ConditionsCataract, Type 2 Diabetes MellitusArmsKetorolac
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Molecular signaling in bone cells: Regulation of cell differentiation and survival.Advances in protein chemistry and structural biology · 2019
    Review
  7. FasL Modulates Expression ofFrontiers in physiology · 2018
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Natasa KovacicUniversity of Zagreb School of Medicine, Department of Anatomy, Zagreb, HR-10000, Croatia. natasa@mef.hr
Danka Grcevic
Vedran Katavic
Ivan Kresimir Lukic
Ana Marusic
University of Zagreb · HRUniversity of Split · HR

Funding

Wellcome Trust 073828Wellcome Trust CRIGS 073828/Z/03/Z
6 · The paper itself

Abstract

importance of the fieldFas receptor is a mediator of the external apoptotic pathway in many cells and tissues. It is proposed that Fas receptor mediates osteoresorptive effects of estrogen deficiency and local/systemic inflammation. AREAS COVERED IN THIS REVIEW: This review covers the past two decades of research on the expression and function of the Fas-Fas ligand system on bone cells, involvement in the pathogenesis of osteoresorption and potential therapeutic modulation. WHAT THE READER WILL GAIN: We review the structure, biological function and intracellular signaling pathways of the Fas-Fas ligand system emphasizing the role of the non-apoptotic signaling pathways in bone cells, particularly osteoblast differentiation. We also present data on the in vitro expression and function of the Fas-Fas ligand system on osteoblast/osteoclast lineage cells, animal and human studies confirming its involvement in osteoresorptive disorders and potential therapeutic approaches to modulate its function. TAKE HOME MESSAGE: Tissue specific therapeutic approaches need to be established to modify the Fas-Fas ligand system in osteoresorptive disorders as systemic targeting has many side effects. The most promising approach would be to target Fas signaling molecules coupled with osteoblast/osteoclast differentiation pathways, but a precise definition of these targets is still needed.

Indexed as

AnimalsApoptosisBone and BonesBone ResorptionCell DifferentiationCell LineageFas Ligand Proteinfas ReceptorGene ExpressionHumansMolecular Targeted TherapyOsteoblastsOsteoclastsOsteogenesisSignal TransductionFas Ligand Proteinfas Receptor

Identifiers

PMID20854180
PMCPMC3035871
OpenAlexW2036142347

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.